The IPO was entirely a fresh issue of 22.41 lakh shares.
Incorporated in 2019, Asston Pharmaceuticals manufactures and exports a wide range of pharmaceutical formulations, including tablets, syrups, capsules, and sachets.
The company focuses on key therapeutic categories such as analgesics, antibiotics, antifungals, and vitamins, with products like Albendazole, Diclofenac, and Ferrovit Syrup forming part of its portfolio.
Asston operates on both direct sales and contract manufacturing models and holds certifications from central and state FDA, NQA, and follows Quality Management System (QMS) standards. As of July 2025, it has a workforce of 52 employees, including 6 on contract.
Financial Snapshot
The company posted robust growth in FY25, with revenue up 62% year-on-year to Rs 25.61 crore, and PAT rising 218% to Rs 4.33 crore. EBITDA also jumped to Rs 6.16 crore from Rs 2.55 crore in the previous year.
With a 24% GMP, strong financials, and growing demand for Indian pharma exports, Asston’s listing is expected to see healthy investor interest, though the SME segment’s volatility remains a caveat. All eyes will now be on the stock’s opening tick on Wednesday.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)